ANNUAL RESULTS for the year ended 31 August 2023



Agenda

- **01** Review of the year
- **02** Financial results
- **03** Trading performance
- 04 Strategy and outlook
- 05 Questions







Bertina Engelbrecht



Review of the year



- Performance continues to prove the resilience and defensiveness of the group
 - Adjusted dHEPS up 11.5%
- Clicks opened 850th store and 700th pharmacy
- Market share gains in all categories
- Acquisitions of Sorbet, M-Kem and 180 Degrees
- Better performance from UPD in H2
- Record capital investment

ESG integrated into the business

 $\underset{\tiny \overline{L\ I\ M\ I\ T\ E\ D}}{CLICKS} \ GROUP$

- In FTSE4Good Index for last seven years
- AA ESG rating from MSCI
- Top Employer* in retail sector for 7th year
- Diversity leadership recognised in The Gender Mainstreaming Awards Africa
- Solar on all owned DCs and head office, and investing in solar battery storage
- Supporting national health initiatives
 - Girls on the Go / Students on the Go
 - Phelophepa clinic train and Gift of the Givers







Gordon Traill



Financial highlights



Turnover up

8.2%**

Retail turnover up
12.2%**

UPD reported turnover up **1.5%**

Operating margin

up from 8.4%* to

8.7%

Adjusted dHEPS up

11.5%*

Total dHEPS up

1.1%

to 1 045 cps

Cash generated by operations

R5.9 bn

Returned to shareholders

R2.3 bn

2.8m shares repurchased

Return on equity

down from 48.0% to

43.6%

Total dividend up

6.6%

to 679 cps

^{*} FY2022 adjusted for SASRIA insurance proceeds received

^{**} Excluding vaccinations in both periods

Impact of insurance payout on base



R'm	2023	Reported 2022	Adjustment (see notes below)	Adjusted 2022	% change
Turnover	41 622	39 587		39 587	
Gross profit	9 314	8 432		8 432	
Other income	2 846	2 867	(325)1	2 542	
Expenses	(8 537)	(7 649)		(7 649)	
Operating profit	3 623	3 650	(325)	3 325	9.0
Capital items	(7)	163	(167)2	(4)	
Taxation	(934)	(1 000)	136	(864)	
Headline earnings	2 543	2 523	(235) ³	2 288	11.1
dHEPS (cents)	1 044.5	1 032.7	(96.1)	936.6	11.5

Notes:

- 1. Second and third SASRIA payments
- 2. PPE insurance portion
- 3. Insurance income portion after tax

Turnover



R'm	2023	2022	% change	% same stores growth*	% inflation
Retail	31 725	29 405	7.9	7.7	7.0
Distribution	17 175	16 922	1.5		1.0
Intragroup turnover	(7 278)	(6 740)	8.0		
Total group	41 622	39 587	5.1		4.9

- Retail turnover up 12.2% excluding vaccinations
 - Administered R4m vaccinations in 2023 versus R1.1bn in 2022
- UPD growth impacted by low SEP increase, post systems implementation and switch of products from preferred supplier to bulk distribution

^{*} Excluding vaccinations in both periods

Total income



R'm	2023	2022	% change	2023 % margin	2022 % margin
Retail	10 836	9 662	12.2	34.2	32.9
Distribution	1 600	1 544	3.6	9.3	9.1
Intragroup turnover	(276)	(232)			
Total group	12 160	10 974	10.8	29.2	27.7

- Retail margin continued to benefit from recovery in Beauty, strong growth in private label and end of vaccination programme
- Improved shrink and waste in UPD

Operating expenditure – Retail



R'm	2023	2022	% change
Depreciation – PPE	511	462	10.7
Depreciation – ROU asset	903	820	10.0
Occupancy costs	187	160	17.2
Employment costs	4 035	3 678	9.7
Other operating costs	2 041	1 773	15.1
Total retail costs	7 677	6 893	11.4
% of turnover	24.2%	23.4%	
Finance costs – lease liability	200	183	8.9

- Comparable retail cost growth 7.4%
- Other operating costs impacted by insurance and R40m diesel for generators

Operating expenditure – Distribution



R'm	2023	2022	% change
Depreciation – PPE	29	29	2.4
Depreciation – ROU asset	18	10	79.0
Occupancy costs	4	5	(26.1)
Employment costs	359	325	10.3
Other operating costs	703	613	14.8
Total distribution costs	1 113	982	13.4

- Employment costs increased during systems rollout
- R13.5m in diesel costs during load shedding
- Higher insurance premiums

Operating profit




R'm	2023	2022	% change	2023 % margin	2022 % margin
Retail	3 159	2 769	14.1	10.0	9.4
Distribution	488	563	(13.4)	2.8	3.3
Intragroup	(24)	(7)			
Total group	3 623	3 325	9.0	8.7	8.4

- Benefit of recovery of higher margin categories in Retail; impact of low margin vaccinations in FY2022
- UPD impacted by load shedding, higher insurance costs, low SEP increase and labour cost inefficiencies in H1

Growth in turnover, profit and margin





^{*} Continuing operations, FY2021 and FY2022 operating profit and margin adjusted for impact of civil unrest

Inventory




	Days in stock		Ir	Inventory (R'm)	
	2023	2022	2023	2022	% change
Retail	75	71	4 656	4 109	13.3
Distribution	39	48	1 805	2 183	(17.3)
Intragroup inventory			(151)	(128)	
Total group	71	72	6 310	6 164	2.4

- Retail days in prior year benefited from much faster stock turn of vaccines
- Improved stock management in UPD and benefit of lower Covid stocks required

Cash management





- R392m additional shares repurchased post year end
- R1.2 billion final dividend to be paid to shareholders in January 2024

Acquisitions



- **M-Kem** 1 April 2023
 - 24-hour specialised pharmacy in Cape Town
 - Annual turnover of R240m and EBIT of R8-10m.
- 1 May 2023
 - Pharmacy software development company
 - R40-50m p.a. cost efficiencies and revenue generation on 3-year roll out
- **Jorbετ** 1 June 2023
 - Beauty salon franchise chain of 194 outlets; products sold in salons & Clicks stores
 - Annual EBIT of R25-30m

Capital expenditure



- R880m capex planned for FY2024
 - R487m on stores:
 - 40 50 new Clicks stores and 40 50 new pharmacies
 - 50 60 store refurbishments
 - R393m on infrastructure:
 - R77m on UPD IT and warehouse equipment
 - R316m on retail systems and infrastructure including 6 000m² expansion of Centurion DC
 - Investment of R36m in solar and battery storage in FY2023 and FY2024


Medium-term financial targets



	Achieved in FY2023	Medium-term target
ROE (%)	43.6	40 – 50
ROIC excluding IFRS 16 (%)	41.5	40 – 50
ROIC (%)	28.4	20 – 30
ROA (%)	13.8	11 – 15
Net working capital days	34	30 – 35
Group operating margin (%)	8.7	8.0 - 9.0
Retail	10.0	9.0 – 10.0
Distribution	2.8	2.8 - 3.3
Dividend payout ratio (%)	65	60 – 65

Sustained financial performance









Bertina Engelbrecht







Clicks business review

Retail sales performance



	% change*	% contribution
Pharmacy	9.7	28.2
Front shop health	5.3	25.4
Beauty and personal care	18.3	31.0
General merchandise	15.1	15.4
Total turnover	12.2	100.0

- Comparable stores turnover growth of 7.7%*
 - Inflation 7.0%
 - Volume growth of 0.7%

^{*} Excluding vaccinations in both periods

Market shares



%	2023	2022
Health		
Retail pharmacy*	24.0	23.6
Front shop health**	32.8	32.3
Baby**	21.0	20.5
Beauty		
Skincare**	43.6	42.1
Haircare**	33.0	32.3
Personal care**	21.1	20.2
General merchandise		
Small electrical appliances**	19.5	18.4

^{*} Per IQVIA (Private Retail Pharmacy \$1-6) (restated)

^{**} Per AC Nielsen (restated)



- Maintaining value
 - Price competitive with all national retailers
 - Promotional sales +14.9%
 to 43.6% of turnover
 - In pharmacy, generics +8.8% to 59% of sales and 70% of volume
 - R689 million cashback paid to ClubCard members

Clicks price index* vs:				
Retailer A	98.2			
Retailer B	99.0			
Retailer C	99.4			
Retailer D	94.8			

* Excluding all promotional pricing, bulk deals and 3 for 2 promotions





- Differentiating our product offer
 - Private label +15.4% to 25.2% of sales (front shop 30.3%, pharmacy 11.3%)
 - Clicks Made 4 Baby nappy range won SA
 Product of the Year 2023



- Roll out of new look beauty halls
- Strong performance from Sorbet
- Extending Clicks Baby store-in-stores and standalone stores





- Engaging customers through personalisation
 - 10.4m active ClubCard members, 80.2% of sales
 - Best strategic use of data analytics / CRM applications¹
 - Top brand for experience, function and meaning²
 - Coolest health and beauty store³
 - 1. South African Loyalty Awards 2023
 - Kantar BrandZ 2023 Top 30 Most Valuable South African Brands
 - Sunday Times GenNext 2023 Awards





- Extending convenience
 - 885 Clicks stores with 711 pharmacies
 - 50% of population < 5.1km of a pharmacy
 - Successful onboarding of M-Kem
 - 228 stores located in low income areas (22.5% of retail turnover), with 18 stores opened this year
 - Online purchases 1.2% of front shop, and together with 'research online purchase offline' (ROPO), comprise 4% of sales

Format	Total
Convenience	664
Destination	221
Total	885








UPD business review

Fine wholesale turnover





- Wholesale turnover up 3.5%
 - Impact of systems change on Clicks purchases from UPD in H1
 - Hospital volumes +10.8% shift in case and product mix
- Wholesale market share down from 28.8% to 28.0%*

^{*} MAT per IQVIA (restated)

Review of the year



- Total managed turnover +4.8% to R32.1bn
 - Rationalising portfolio to focus on profitable bulk contracts
- Proven business continuity credentials
- Improved H2 performance
- Generic medicines +5.3% to 73% of volume
- ERP and WMS implementation
 - Lea Glen DC went live on 1 September 2023
 - Systems are stable, with further efficiencies to be realised in FY2024



04

Strategy and outlook

Bertina Engelbrecht

Group strategic objectives





Increase customer appeal and access by expanding the store, pharmacy and online presence



Accelerate market share gains in pharmacy and core front shop categories



Promote UPD's national pharmaceutical wholesale and distribution services to grow market share



Deliver operational excellence with an efficient centralised supply chain



Create an inclusive and transformed organisation with a strong talent pipeline to support business growth



Ensure sustainability through efficient cash and capital management and adopt robust environmental, social and governance practices

Outlook



- Consumer environment will remain extremely constrained
- Target of 1 200 Clicks stores
 - Plan to open 40 50 stores and pharmacies per year
- Focus on innovation in technology, products and service
- Commitment to carbon neutrality
- Business model remains resilient, with proven ability to adapt to changing market dynamics
- Confident of the group's ability to continue delivering on medium-term targets







Disclaimer



Clicks Group has acted in good faith and has made every reasonable effort to ensure the accuracy and completeness of the information contained in this presentation, including all information that may be defined as 'forward-looking statements' within the meaning of United States securities legislation.

Forward-looking statements may be identified by words such as 'believe', 'anticipate', 'expect', 'plan', 'estimate', 'intend', 'project', 'target', 'predict' and 'hope'.

Forward-looking statements are not statements of fact, but statements by the management of Clicks Group based on its current estimates, projections, expectations, beliefs and assumptions regarding the group's future performance.

No assurance can be given that forward-looking statements will prove to be correct and undue reliance should not be placed on such statements.

The risks and uncertainties inherent in the forward-looking statements contained in this presentation include, but are not limited to: changes to IFRS and the interpretations, applications and practices subject thereto as they apply to past, present and future periods; domestic business and market conditions; changes in the domestic regulatory and legislative environments; changes to domestic operational, social, economic and political risks; and the effects of both current and future litigation.

Clicks Group does not undertake to update any forward-looking statements contained in this presentation and does not assume responsibility for any loss or damage whatsoever and howsoever arising as a result of the reliance by any party thereon, including, but not limited to, loss of earnings, profits, or consequential loss or damage.